← All trials
NCT05618223
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Nov 16, 2022
- Last posted
- Nov 21, 2022
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universitas Sebelas MaretLead sponsor
- Universitas Sebelas MaretOverall official - principal investigator
- Universitas Sebelas MaretReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.